No Overall Survival Difference With PARP Inhibitor Maintenance Therapy in Ovarian Cancer

Data from the ENGOT-OV16/NOVA study show NO difference in overall survival (OS) for patients with platinum-sensitive recurrent ovarian cancer who received poly (ADP-ribose) polymerase (PARP) inhibitor Niraparib maintenance therapy and those who did not. 

https://www.pharmacytimes.com/view/long-term-follow-up-shows-no-overall-survival-difference-with-parp-inhibitor-maintenance-therapy-in-ovarian-cancer

OS hazard ratio numerically favored Niraparib in the germline BRCA mutation cohort and favored placebo in the non-germline BRCA mutation cohort (approximately 85% of epithelial ovarian cancer patients are in this group!).